OBJECTIVES: Uterine MMMTs are aggressive malignancies that are rarely cured by purely local therapies. Effective chemotherapy is needed. The phase III proven, ifosfamide-based combinations are inconvenient and costly. Carboplatin and paclitaxel (CT) are easy to deliver and is effective against endometrial carcinoma and should be against MMMT (as they are now regarded as epithelial in nature). METHODS: A review of all women with uterine MMMT treated with CT. Paclitaxel 175 mg/m2 over 3 h preceded carboplatin (AUC 5-6) every 4 weeks for 3-6 cycles+/-subsequent pelvic irradiation. RESULTS: Twenty-eight newly diagnosed women (20 evaluable) and 12 recurrent (11 evaluable) were treated. Response rates were 60% (12 of 20, CR 5, PR 7) and 55% (6 of 11, CR 2, PR 4) with median PFS of 16 and 12 months. Dose reduction occurred in 5%, treatment delay in 10%. CONCLUSIONS: Carboplatin-paclitaxel is effective against uterine MMMT, with similar efficacy to ifosfamide combinations. It is more convenient, less costly and easy to deliver.
OBJECTIVES: Uterine MMMTs are aggressive malignancies that are rarely cured by purely local therapies. Effective chemotherapy is needed. The phase III proven, ifosfamide-based combinations are inconvenient and costly. Carboplatin and paclitaxel (CT) are easy to deliver and is effective against endometrial carcinoma and should be against MMMT (as they are now regarded as epithelial in nature). METHODS: A review of all women with uterine MMMT treated with CT. Paclitaxel 175 mg/m2 over 3 h preceded carboplatin (AUC 5-6) every 4 weeks for 3-6 cycles+/-subsequent pelvic irradiation. RESULTS: Twenty-eight newly diagnosed women (20 evaluable) and 12 recurrent (11 evaluable) were treated. Response rates were 60% (12 of 20, CR 5, PR 7) and 55% (6 of 11, CR 2, PR 4) with median PFS of 16 and 12 months. Dose reduction occurred in 5%, treatment delay in 10%. CONCLUSIONS:Carboplatin-paclitaxel is effective against uterine MMMT, with similar efficacy to ifosfamide combinations. It is more convenient, less costly and easy to deliver.
Authors: Gunjal Garg; Cecilia Yee; Kendra Schwartz; David G Mutch; Robert T Morris; Matthew A Powell Journal: Gynecol Oncol Date: 2014-02-19 Impact factor: 5.482
Authors: Matthew A Powell; Virginia L Filiaci; Peter G Rose; Robert S Mannel; Parviz Hanjani; Koen Degeest; Brigitte E Miller; Nobuyuki Susumu; Frederick R Ueland Journal: J Clin Oncol Date: 2010-04-26 Impact factor: 44.544
Authors: Susana M Campos; William E Brady; Katherine M Moxley; Roisin E O'Cearbhaill; Paula S Lee; Paul A DiSilvestro; Jacob Rotmensch; Peter G Rose; Premal H Thaker; David M O'Malley; Parviz Hanjani; Rosemary E Zuna; Martee L Hensley Journal: Gynecol Oncol Date: 2014-03-01 Impact factor: 5.482
Authors: C Kosmas; G Vorgias; G Tsakonas; P Politis; T Daladimos; E Panagiotidi; T Papachrysanthou; D Moschovis; N Kalinoglou; N Tsavaris; A Karabelis; N Mylonakis Journal: Br J Cancer Date: 2011-08-16 Impact factor: 7.640